Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06760637
What this trial is testing

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Who this might be right for
Breast Cancer
Pfizer 1,035
Testing effectiveness (Phase 2)Study completedNCT01565200
What this trial is testing

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Who this might be right for
HER-2 Positive Breast Cancer
Jules Bordet Institute 90
Not applicableActive Not RecruitingNCT01093612
What this trial is testing

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast CancerStage IV Breast Cancer
City of Hope Medical Center 18
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Testing effectiveness (Phase 2)Ended earlyNCT04249622
What this trial is testing

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+18 more
Mayo Clinic 20
Early research (Phase 1)Ended earlyNCT07214662
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT03202862
What this trial is testing

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Fudan University 50
Large-scale testing (Phase 3)Active Not RecruitingNCT02625441
What this trial is testing

Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Helsinki University Central Hospital 516
Testing effectiveness (Phase 2)UnknownNCT05429294
What this trial is testing

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Who this might be right for
HER2-positive Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University 209
Testing effectiveness (Phase 2)UnknownNCT01016886
What this trial is testing

Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research

Who this might be right for
Breast CancerHeart Failure
University of Alberta 99
Large-scale testing (Phase 3)UnknownNCT03927456
What this trial is testing

SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 357
Testing effectiveness (Phase 2)Active Not RecruitingNCT03161353
What this trial is testing

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Who this might be right for
Breast Cancer
MedSIR 377
Testing effectiveness (Phase 2)UnknownNCT05420779
What this trial is testing

Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Who this might be right for
Breast Cancer Metastatic
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. 125
Early research (Phase 1)Ended earlyNCT03294694
What this trial is testing

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Who this might be right for
Metastatic Hormone-Receptor-Positive (HR+) Breast CancerHER2-Negative Breast CancerMetastatic Epithelial Ovarian Cancer
Dana-Farber Cancer Institute 33
Post-approval studies (Phase 4)Study completedNCT04707196
What this trial is testing

Abemaciclib in Indian Women With Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 200
Testing effectiveness (Phase 2)Study completedNCT00769470
What this trial is testing

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Breast Cancer
Translational Oncology Research International 18
Large-scale testing (Phase 3)Active Not RecruitingNCT05132582
What this trial is testing

Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 654
Testing effectiveness (Phase 2)UnknownNCT05328440
What this trial is testing

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Who this might be right for
Breast Neoplasms
Henan Cancer Hospital 120
Testing effectiveness (Phase 2)UnknownNCT00931450
What this trial is testing

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Institut Català d'Oncologia 70
Testing effectiveness (Phase 2)UnknownNCT06361979
What this trial is testing

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Who this might be right for
Breasr Cancer
Huihua Xiong 30
Next Page